Publications by authors named "A Oaknin"

Claim this Profile
T
The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201.
Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D'Hondt, Bradley J Monk, Ana Oaknin

Future Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc.
Munetaka Takekuma, Shin Nishio, Satoshi Yamaguchi, Mayu Yunokawa, Hiroshi Nishio, Ana Oaknin

J Gynecol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.
Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D'Hondt, Bradley J Monk, Ana Oaknin

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study.
R S Kristeleit, S Ghamande, A Lisyanskaya, A Oaknin, E Prendergast

Ann Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025.
Nicole Concin, Xavier Matias-Guiu, David Cibula, Nicoletta Colombo, Carien L Creutzberg, Ana Oaknin

Lancet Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis